Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

senior vice president and head of Chief Medical Office at Novo Nordisk. “Our broad and robust semaglutide data presented at ECO, including its impact on weight loss in a real-world setting and ...

Novo Nordisk's (NVO) investors are worried its competition ... Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Novo Nordisk also highlighted the completion of its REDEFINE 2 trial for CagriSema, its next-generation obesity drug. The treatment ... for US approval of oral semaglutide 25 mg, with the ...

Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. ...

Sales growth has resulted in periodic supply constraints and related drug shortage notifications ... In February 2025, Novo Nordisk submitted oral semaglutide 25 mg to the FDA, with the potential ...

One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk’s outlook is brightening. Novo Nordisk, the Danish company that produces the semaglutide ...